3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Small Cell Lung Carcinoma
27
Lymphoma, Large B-Cell, Diffuse
10
Lung Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Lymphoma, Non-Hodgkin
6
Lymphoma, B-Cell
6
Hodgkin Disease
6
Burkitt Lymphoma
6
Neuroblastoma
5
Medulloblastoma
5
Neoplasms, Germ Cell and Embryonal
4
Leukemia, Myeloid, Acute
4
Small Cell Lung Cancer Extensive Stage
3
Seminoma
3
Retinoblastoma
3
Recurrence
3
Ovarian Neoplasms
3
Multiple Myeloma
3
Lymphoma
3
Carcinoma, Neuroendocrine
3
Brain Neoplasms
3
Wilms Tumor
2
Urinary Bladder Neoplasms
2
Teratoma
2
Sarcoma, Ewing
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Neuroectodermal Tumors, Primitive
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Interventions
enzalutamide
4
Docetaxel
2
pembrolizumab
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
abiraterone
1
Prednisone
1
PF06821497
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Castration-Resistant Prostate Cancer
×
Etoposide
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled